A Two Parts, Biomarker Study to Identify Genetic Aberrations Predictive for Response on Everolimus in Solid Tumors Without Regular Treatment Options

Trial Profile

A Two Parts, Biomarker Study to Identify Genetic Aberrations Predictive for Response on Everolimus in Solid Tumors Without Regular Treatment Options

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Solid tumours
  • Focus Biomarker; Pharmacodynamics; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 17 Aug 2012 Actual initiation date (1 Aug 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 11 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top